Last updated on August 2019

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine


Brief description of study

The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine.

The study will last about 6 weeks, and includes 4 visits.

Clinical Study Identifier: NCT03988088

Find a site near you

Start Over

Children's Hospital of Philadelphia

Philadelphia, PA United States
8.05miles
  Connect »